MET与ERBB双重抑制克服奥希替尼耐药晚期非小细胞肺癌的瘤内可塑性
研究分析一例EGFR T790M突变NSCLC患者脑转移灶在长期奥希替尼治疗后出现MET基因扩增,小鼠原位移植瘤中卡马替尼联合阿法替尼完全抑制肿瘤生长,单药治疗则出现KRAS G12C克隆。单细胞分析揭示瘤内异质性,并在接受不同EGFR-TKI治疗的患者中检测到低频KRAS G12C等位基因。
要点
- 奥希替尼耐药脑转移灶中检测到MET基因扩增。
- 卡马替尼联合阿法替尼在小鼠中完全抑制肿瘤生长。
- 单药卡马替尼或阿法替尼治疗出现KRAS G12C克隆。
核心结论
- EGFR突变肺癌患者对后续EGFR-TKI治疗线的获得性耐药可能诱导基因可塑性。
- 在奥希替尼耐药且获得MET扩增的肿瘤中评估了肿瘤异质性的生物学见解,并提出此情况下的新治疗策略。
研究设计与样本
- 采用Amplicon-seq分析索引患者原发和转移灶不同时间点样本及对应不同治疗组的患者来源原位异种移植瘤。
- 采用微滴数字PCR分析20例基线或进展至不同TKI治疗线的NSCLC患者原发或转移标本。
- 单细胞分析取自幼年裸鼠脑内原位生长的转移灶。
主要发现
- 在一例EGFR T790M突变NSCLC患者的脑转移灶中,长期奥希替尼治疗后检测到MET基因扩增。
- 卡马替尼(c-MET抑制剂)联合阿法替尼(ErbB-1/2/4抑制剂)完全抑制了小鼠原位注射该脑转移灶来源细胞的肿瘤生长。
- 在单用卡马替尼或阿法替尼治疗的小鼠中观察到KRAS G12C克隆出现。
- 单细胞基因表达分析揭示瘤内异质性,提示存在KRAS驱动的亚克隆。
- 在接受各种EGFR-TKI治疗的患者中也检测到低频KRAS G12C等位基因。
关键数值与推荐
- Amplicon-seq分析样本来自索引患者原发和转移灶及对应不同治疗组的患者来源原位异种移植瘤,均为福尔马林固定石蜡包埋并经病理学家评估。
- 微滴数字PCR分析20例NSCLC患者,标本为原发肿瘤或转移灶的福尔马林固定石蜡包埋块。
- 单细胞分析取自幼年裸鼠脑内原位生长的转移灶,于-80°C冻存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M. Different mechanisms of acquired resistance to third-generation EGFR-TKIs have been proposed. It is therefore crucial to identify new and effective strategies to overcome successive acquired mechanisms of resistance. METHODS: For Amplicon-seq analysis, samples from the index patient (primary and metastasis lesions at different timepoints) as well as the patient-derived orthotopic xenograft tumors corresponding to the different treatment arms were used. All samples were formalin-fixed paraffin-embedded, selected and evaluated by a pathologist. For droplet digital PCR, 20 patients diagnosed with NSCLC at baseline or progression to different lines of TKI therapies were selected. Formalin-fixed paraffin-embedded blocks corresponding to either primary tumor or metastasis specimens were used for analysis. For single-cell analysis, orthotopically grown metastases were dissected from the brain of an athymic nu/nu mouse and cryopreserved at -80°C. RESULTS: In a brain metastasis lesion from a NSCLC patient presenting an EGFR T790M mutation, we detected MET gene amplification after prolonged treatment with osimertinib. Importantly, the combination of capmatinib (c-MET inhibitor) and afatinib (ErbB-1/2/4 inhibitor) completely suppressed tumor growth in mice orthotopically injected with cells derived from this brain metastasis. In those mice treated with capmatinib or afatinib as monotherapy, we observed the emergence of KRAS G12C clones. Single-cell gene expression analyses also revealed intratumor heterogeneity, indicating the presence of a KRAS-driven subclone. We also detected low-frequent KRAS G12C alleles in patients treated with various EGFR-TKIs. CONCLUSION: Acquired resistance to subsequent EGFR-TKI treatment lines in EGFR-mutant lung cancer patients may induce genetic plasticity. We assess the biological insights of tumor heterogeneity in an osimertinib-resistant tumor with acquired MET-amplification and propose new treatment strategies in this situation.
引用
- Martinez-Marti A, Felip E, Matito J, et al. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2017. PMID: 28961841. doi:10.1093/annonc/mdx396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。